Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

Joan H.q. Shen, Qi Shen, Holly Yu, Jin Shei Lai, Jennifer L. Beaumont, Zhenxin Zhang, Huali Wang, Seong Yoon Kim, Christopher Chen, Timothy Kwok, Shuu‐Jiun Wang, Dong Young Lee, John Harrison, Jeffrey L. CummingsPubMed 2014

TL;DR

This study validates a suite of Alzheimer's disease (AD) assessment tools (ADAS-Cog, DAD, NTB) in Asian populations, finding them reliable, valid, and responsive to disease progression. This is crucial for conducting global clinical trials and improving AD diagnosis and management in Asia, where dementia prevalence is high.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a growing global health concern, particularly in Asia, which has the highest number of individuals with dementia. However, clinical trials and research in this region have been hampered by a lack of validated assessment tools that are culturally appropriate and reliable across diverse Asian populations. Existing tools, often developed and validated in Western countries, may not accurately capture the nuances of AD in Asian individuals due to linguistic and cultural differences. This study aims to bridge this gap by rigorously evaluating the psychometric properties of key AD assessment instruments in a multi-center, multi-country Asian cohort.

Methods

The researchers employed a multicenter, longitudinal, observational design. They conducted a comprehensive psychometric evaluation of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and the Neuropsychological Test Battery (NTB). This evaluation included:

  • Test-retest reliability: Assessed by calculating intraclass correlation coefficients (ICCs) between screening and baseline visits (25-31 days apart).
  • Inter- and intra-rater reliability: Evaluated using videotaped assessments.
  • Construct validity: Examined through convergent and divergent validity using Spearman correlation coefficients.
  • Discriminant validity: Assessed by comparing mean scores between AD patients and healthy controls using ANCOVA, controlling for age and education. They also compared AD participants with mild vs. moderate/severe disease, and across different regions.
  • Responsiveness to change: Measured by analyzing longitudinal data over 78 weeks using mixed-effects linear models, assessing the magnitude of change over time.

A rigorous translation and cultural adaptation process was undertaken for all instruments to ensure conceptual equivalence and cultural relevance across Simplified Chinese, Traditional Chinese, English, and Korean.

Datasets

The study utilized data from:

  • 251 participants with mild to moderate Alzheimer's disease (AD)
  • 51 healthy control participants

These participants were recruited from multiple sites across Mainland China, Taiwan, Singapore, Hong Kong, and South Korea. The study involved longitudinal data collection over approximately 78 weeks (1.5 years).

Key Insights and Ideas

  • Bridging the Asian Assessment Gap: The most significant insight is the successful validation of AD assessment tools in a diverse Asian cohort. This provides much-needed evidence for their use in future clinical trials and research within the region.
  • Cultural Adaptation is Key: The emphasis on a rigorous translation and cultural adaptation process highlights the importance of ensuring instruments are not just linguistically accurate but also culturally relevant for reliable assessment across different populations.
  • ADAS-Cog, DAD, and NTB are Robust: The study confirms that these instruments are not only reliable and valid but also sensitive to the progression of AD over time in Asian individuals.
  • Disease Severity Matters: The findings underscore the strong correlation between AD severity and poorer performance on most cognitive and functional assessments, reinforcing their utility in tracking disease progression.
  • ApoE4 Prevalence: The study noted a higher prevalence of the ApoE4 allele in AD participants compared to controls, consistent with existing literature, and found it had some association with specific NTB executive function scores.

Key Results

  • Reliability: Test-retest reliability was consistently good, with ICCs better than 0.70 for all tests. Inter- and intra-rater reliability were also high (≥ 0.91 for most measures).
  • Validity:
    • Discriminant Validity: AD participants performed significantly worse than healthy controls across all measures (P < 0.001) with large effect sizes.
  • Convergent Validity: ADAS-Cog, MMSE, and CDR-SB showed significant correlations with NTB executive function and memory scores. DAD and Dependence Scale also correlated with NTB executive function and memory.
  • Responsiveness:
    • Longitudinal Change: AD participants showed significant worsening over time on most measures, while healthy controls remained relatively stable or showed minimal change.
  • Effect Sizes: Responsiveness index values were substantial, ranging from 0.14 (Memory Function) to 22.31 (DAD), indicating the instruments' sensitivity to change.
  • Floor/Ceiling Effects: The ADAS-Cog showed no floor or ceiling effects. For the NTB, some subtests had floor effects in AD participants, but overall, the battery demonstrated good performance characteristics.
  • Regional Differences: While not the primary focus, some regional differences in assessment scores were observed, particularly for DAD, CDR-SB, and NTB Executive Function, suggesting the need for careful interpretation when comparing across regions.

Limitations and Future Work

  • Limited Geographic Scope: The study was limited to five Asian countries, and results may not be generalizable to all Asian populations.
  • Unequal Sample Sizes: Sample sizes within specific regions were unequal, with only China and Korea having sufficient numbers for robust subgroup analyses. This limits the potential for examining the impact of cultural differences in detail.
  • Future Directions: The authors suggest future studies should recruit more diverse samples across a wider range of Asian regions to further enhance generalizability. They also highlight the need for continued investigation into the ApoE4 carrier status in Asian AD patients. The study provides a strong foundation for future AD research and clinical trials in Asia, emphasizing the potential for collaborative, cross-country efforts.

Summary updated

Abstract

There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.
BibTeX
@inproceedings{shen2014validation,
  author = {Joan H.Q. Shen and Qi Shen and Holly Yu and Jin Shei Lai and Jennifer L. Beaumont and Zhenxin Zhang and Huali Wang and Seong Yoon Kim and Christopher Chen and Timothy Kwok and Shuu‐Jiun Wang and Dong Young Lee and John Harrison and Jeffrey L. Cummings},
  title = {{Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.}},
  booktitle = {PubMed},
  year = {2014},
}
Figure